Data on long-term survival of the NOD/Shi-scid IL-2Rγnull (NOG) mouse in two facilities

Yuji Yamashita; Tamio Sato; Kaori Noishiki; Kinji Kobayashi; Asako Uchiyama; Hiroyuki Izumi; Takashi Tamura; Masayuki Shikamura; Yu Oinishi; Miho Saito; Shin Kawamata

doi:10.2131/jts.46.453

Original Article

Data on long-term survival of the NOD/Shi-scid IL-2Rγ^null (NOG) mouse in two facilities

Yuji Yamashita, Tamio Sato, Kaori Noishiki, Kinji Kobayashi, Asako Uchiyama, Hiroyuki Izumi, Takashi Tamura, Masayuki Shikamura, Yu Oinishi, Miho Saito, Shin Kawamata

Author information

Keywords: NOG mice, Tumorigenicity, Survival rate, Human cell-based therapy products, Histopathology

JOURNAL FREE ACCESS FULL-TEXT HTML
Supplementary material

2021 Volume 46 Issue 10 Pages 453-469

DOI https://doi.org/10.2131/jts.46.453

Details

Abstract

The objective of this study was to investigate an appropriate observation period for an evaluation of tumorigenicity in NOD/Shi-scid IL-2 Rγ^null (NOG) mice. At SNBL, 19 male and 19 female NOG mice were observed the general condition from 7 weeks old up to 68 weeks old and at FBRI, 7 male and 16 female NOG mice were observed the general condition throughout the lifespan from 7 weeks old. The survival rate started to decline rapidly around 54 to 56 weeks of age in both facilities without a facility difference. Based on these survival data, it seems reasonable to terminate a tumorigenicity study at 52 weeks of age.

Corresponding author

Register with J-STAGE for free!